Follow
Andreas Stallmach
Andreas Stallmach
Unknown affiliation
Verified email at med.uni-jena.de
Title
Cited by
Cited by
Year
NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal α-defensin expression
J Wehkamp, J Harder, M Weichenthal, M Schwab, E Schäffeler, M Schlee, ...
Gut 53 (11), 1658-1664, 2004
11172004
Peripheral and intestinal regulatory CD4+ CD25high T cells in inflammatory bowel disease
J Maul, C Loddenkemper, P Mundt, E Berg, T Giese, A Stallmach, M Zeitz, ...
Gastroenterology 128 (7), 1868-1878, 2005
8112005
TGF-β and fibrosis in different organs—molecular pathway imprints
D Pohlers, J Brenmoehl, I Löffler, CK Müller, C Leipner, ...
Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1792 (8), 746-756, 2009
7712009
Effects of antibiotics on gut microbiota
K Lange, M Buerger, A Stallmach, T Bruns
Digestive Diseases 34 (3), 260-268, 2016
5502016
Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in …
C Schmidt, T Giese, B Ludwig, I Mueller-Molaian, T Marth, S Zeuzem, ...
Inflammatory bowel diseases 11 (1), 16-23, 2005
3892005
Multisystem inflammatory syndrome in children—initial therapy and outcomes
MBF Son, N Murray, K Friedman, CC Young, MM Newhams, LR Feldstein, ...
New England Journal of Medicine 385 (1), 23-34, 2021
3462021
Drug delivery strategies in the therapy of inflammatory bowel disease
C Lautenschläger, C Schmidt, D Fischer, A Stallmach
Advanced drug delivery reviews 71, 58-76, 2014
2572014
Adverse effects of biologics used for treating IBD
A Stallmach, S Hagel, T Bruns
Best practice & research Clinical gastroenterology 24 (2), 167-182, 2010
2552010
Nano-and microscaled particles for drug targeting to inflamed intestinal mucosa—A first in vivo study in human patients
C Schmidt, C Lautenschlaeger, EM Collnot, M Schumann, C Bojarski, ...
Journal of controlled release 165 (2), 139-145, 2013
2492013
Immunohistochemical and electron microscopic study of interaction of Yersinia enterocolitica serotype O8 with intestinal mucosa during experimental enteritis
C Hanski, U Kutschka, HP Schmoranzer, M Naumann, A Stallmach, ...
Infection and immunity 57 (3), 673-678, 1989
2341989
Increased collagen type III synthesis by fibroblasts isolated from strictures of patients with Crohn's disease
A Stallmach, D Schuppan, HH Riese, H Matthes, EO Riecken
Gastroenterology 102 (6), 1920-1929, 1992
2221992
Diminished expression of integrin adhesion molecules on human colonic epithelial cells during the benign to malign tumour transformation.
A Stallmach, B Von Lampe, H Matthes, G Bornhöft, EO Riecken
Gut 33 (3), 342-346, 1992
1931992
European Crohn’s and Colitis Organisation topical review on treatment withdrawal [‘exit strategies’] in inflammatory bowel disease
G Doherty, KH Katsanos, J Burisch, M Allez, K Papamichael, A Stallmach, ...
Journal of Crohn's and Colitis 12 (1), 17-31, 2018
1902018
Vedolizumab induction therapy for inflammatory bowel disease in clinical practice–a nationwide consecutive German cohort study
DC Baumgart, B Bokemeyer, A Drabik, A Stallmach, S Schreiber, ...
Alimentary pharmacology & therapeutics 43 (10), 1090-1102, 2016
1862016
Updated German guideline on diagnosis and treatment of ulcerative colitis, 2011
A Dignass, JC Preiß, DE Aust, F Autschbach, A Ballauff, G Barretton, ...
Zeitschrift fur Gastroenterologie 49 (9), 1276-1341, 2011
1862011
Rapid mucosal CD4+ T-cell depletion and enteropathy in simian immunodeficiency virus–infected rhesus macaques
S Kewenig, T Schneider, K Hohloch, K Lampe–Dreyer, R Ullrich, N Stolte, ...
Gastroenterology 116 (5), 1115-1123, 1999
1811999
Updated German clinical practice guideline on" Diagnosis and treatment of Crohn's disease" 2014
JC Preiss, B Bokemeyer, HJ Buhr, A Dignaß, W Häuser, F Hartmann, ...
Zeitschrift fur Gastroenterologie 52 (12), 1431-1484, 2014
1782014
Patterns of resistance-associated substitutions in patients with chronic HCV infection following treatment with direct-acting antivirals
J Dietz, S Susser, J Vermehren, KH Peiffer, G Grammatikos, A Berger, ...
Gastroenterology 154 (4), 976-988. e4, 2018
1742018
Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease–a prospective multicenter observational study
A Stallmach, C Langbein, R Atreya, T Bruns, A Dignass, K Ende, J Hampe, ...
Alimentary pharmacology & therapeutics 44 (11-12), 1199-1212, 2016
1692016
Immunosuppressive therapy in Whipple's disease patients is associated with the appearance of gastrointestinal manifestations
R Mahnel, A Kalt, S Ring, A Stallmach, W Strober, T Marth
Official journal of the American College of Gastroenterology| ACG 100 (5 …, 2005
1622005
The system can't perform the operation now. Try again later.
Articles 1–20